PT  - JOURNAL ARTICLE
AU  - Faerman, Afik
AU  - Bishop, James H.
AU  - Stimpson, Katy H.
AU  - Phillips, Angela
AU  - Gülser, Merve
AU  - Amin, Heer
AU  - Nejad, Romina
AU  - DeSouza, Danielle D.
AU  - Geoly, Andrew D.
AU  - Kallioniemi, Elisa
AU  - Jo, Booil
AU  - Williams, Nolan R.
AU  - Spiegel, David
TI  - Modulation of a Stable Neurobehavioral Trait Using Repetitive Transcranial Magnetic Stimulation: A Preregistered Randomized Controlled Trial
AID  - 10.1101/2021.07.08.21260222
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.08.21260222
4099  - http://medrxiv.org/content/early/2021/07/12/2021.07.08.21260222.short
4100  - http://medrxiv.org/content/early/2021/07/12/2021.07.08.21260222.full
AB  - Hypnotizability, one’s ability to experience cognitive, emotional, behavioral, and physical changes in response to suggestions in the context of hypnosis, is a highly stable trait associated with increased functional connectivity between the left dorsolateral prefrontal cortex (L-DLPFC) and dorsal anterior cingulate cortex (dACC). We conducted a preregistered, triple-blinded, randomized controlled trial to test the ability of continuous theta-burst stimulation (cTBS) over a personalized neuroimaging-based L-DLPFC target to temporarily enhance hypnotizability. We tested our hypothesis in 78 patients with fibromyalgia syndrome (FMS), a functional pain disorder for which hypnosis has consistently been shown to be beneficial as a nonpharmacological treatment option. Pre-to-post cTBS change in Hypnotic Induction Profile scores (HIP; a standardized measure of hypnotizability) was significantly greater in the Active versus Sham group. Our findings suggest a causal relationship between L-DLPFC and dACC function and hypnotizability. Dose-response optimization should be further examined to formalize guidelines for future clinical utilization.Trial registration ClinicalTrials.gov NCT02969707Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02969707Funding StatementThis trial was supported by NIH grant R33AT009305 (PIs David Spiegel, M.D. and Nolan R. Williams, M.D.) from the National Center for Complementary and Integrative Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Stanford University Institutional Review Board (IRB), and all participants provided informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding authors, NW and DS, upon reasonable request.